Patents by Inventor Robert W. Herbst

Robert W. Herbst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210299265
    Abstract: The present invention provides a novel method for preparing a cell-binding agent cytotoxic agent conjugate. The method comprises the step of reacting a cell-binding agent with a cytotoxic agent or a cytotoxic agent-linker compound having a reactive group capable of forming a covalent bond with the cell-binding agent at a pH between 4 to 9 in the presence of a buffer solution with high ionic strength, wherein the cell-binding agent comprises a lysine ?-NH2 group that forms a covalent bond with the cytotoxic agent or the cytotoxic agent-linker compound having an amine-reactive group. The cell-binding agent-cytotoxic agent conjugates prepared according to the methods described herein are also included in the present invention.
    Type: Application
    Filed: February 3, 2017
    Publication date: September 30, 2021
    Applicants: IMMUNOGEN, INC., IMMUNOGEN, INC.
    Inventors: Katharine C. Lai, Robert W. Herbst, Scott Alan Hilderbrand
  • Patent number: 10603388
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: March 31, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Gillian Payne, Robert W. Herbst, Juma Bridgewater
  • Publication number: 20190365917
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Application
    Filed: May 9, 2019
    Publication date: December 5, 2019
    Applicant: ImmunoGen, Inc.
    Inventors: Gillian Payne, Robert W. Herbst, Juma Bridgewater
  • Publication number: 20190270769
    Abstract: Methods of producing, purifying, and formulating antibody drug conjugates (ADCs) are provided herein. The methods use continuous conjugation processes, single-pass tangential flow filtration, countercurrent diafiltration, and/or in-line process automation technologies. The methods decrease process times and costs and improve product consistency.
    Type: Application
    Filed: January 11, 2019
    Publication date: September 5, 2019
    Inventors: Daniel F. Milano, Michael R. Reardon, Richard A. Silva, Benjamin M. Hutchins, Robert W. Herbst
  • Publication number: 20190038762
    Abstract: This invention relates to antibody-drug conjugates capable of delivering cytotoxic compounds to cancers expressing the guanylyl cyclase C (GCC) transmembrane cell surface receptor.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., IMMUNOGEN, INC.
    Inventors: Ole Petter VEIBY, Ravi V. J. CHARI, John M. LAMBERT, Katharine C. LAI, Robert W. HERBST, Scott A. HILDERBRAND
  • Publication number: 20170348428
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Application
    Filed: August 16, 2017
    Publication date: December 7, 2017
    Applicant: ImmunoGen, Inc.
    Inventors: Gillian PAYNE, Robert W. HERBST, Juma BRIDGEWATER
  • Publication number: 20160058884
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide administration of such therapeutic compositions within a narrow intended range.
    Type: Application
    Filed: September 2, 2015
    Publication date: March 3, 2016
    Applicant: IMMUNOGEN, INC.
    Inventors: Gillian Payne, Robert W. Herbst, Juma Bridgewater